Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Product preparation issue? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Product preparation issue have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.0% of all adverse event reports for OCRELIZUMAB.

18
Reports of Product preparation issue with OCRELIZUMAB
0.0%
of all OCRELIZUMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Product preparation issue From OCRELIZUMAB?

Of the 18 reports, 2 (11.1%) required hospitalization.

Is Product preparation issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Product preparation issue?

ONABOTULINUMTOXINA (677) COAGULATION FACTOR IX HUMAN\COAGULATION FACTOR VII HUMAN\COAGULATION FACTOR X HUMAN\PROTEIN C\PROTEIN S HUMAN\PROTHROMBIN (252) HUMAN C1-ESTERASE INHIBITOR (238) SOMATROPIN (200) INCOBOTULINUMTOXINA (174) STIRIPENTOL (129) TESAMORELIN (119) ABATACEPT (115) INFLIXIMAB (101) ABOBOTULINUMTOXINA (91)

Which OCRELIZUMAB Alternatives Have Lower Product preparation issue Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Product preparation issue Reports All Drugs Causing Product preparation issue OCRELIZUMAB Demographics